New therapeutic approaches for the prevention and treatment of migraine

@article{Diener2015NewTA,
  title={New therapeutic approaches for the prevention and treatment of migraine},
  author={Hans Christoph Diener and Andrew Charles and Peter J. Goadsby and Dagny Holle},
  journal={The Lancet Neurology},
  year={2015},
  volume={14},
  pages={1010-1022}
}
The management of patients with migraine is often unsatisfactory because available acute and preventive therapies are either ineffective or poorly tolerated. The acute treatment of migraine attacks has been limited to the use of analgesics, combinations of analgesics with caffeine, ergotamines, and the triptans. Successful new approaches for the treatment of acute migraine target calcitonin gene-related peptide (CGRP) and serotonin (5-hydroxytryptamine, 5-HT1F) receptors. Other approaches… Expand
New Therapeutic Approaches for the Treatment of Migraine
TLDR
Future pharmacological target and compounds which have been developed for the acute attacks of migraine including: serotonin 5-HT 1F receptor agonists, nitric oxide synthase inhibitors, calcitonin gene-related peptide (CGRP) receptor antagonists, cation channel subfamily vanilloid member 1 (TRPV1) receptor modulators, glutamate receptors antagonists and PAC1 receptor antagonists are reviewed. Expand
Anti-CGRP monoclonal antibodies in migraine: current perspectives
TLDR
Although not all migraineurs respond to this treatment, and longer administration periods will be needed to assess long-term effects, the results so far obtained are extraordinarily promising and probably represent a turning point for prevention similar to that represented by triptans for abortive treatment in migraine. Expand
UPDATE IN DIAGNOSIS AND TREATMENT OF MIGRAINES
Background Half to three quarters of the adults aged 18 and among those individuals, more than 10% have reported migraine. Aim: To explore the updates of migraine diagnosis and treatment. MethodsExpand
CGRP Receptor Antagonists for the Treatment of Migraine
TLDR
Despite many challenges relating to the target structure, several small-molecule CGRP receptor antagonists have demonstrated clinical efficacy for the acute treatment of migraine although none have reached the market yet. Expand
Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect
TLDR
A general delay of effect in oral antimigraine drugs is strongly indicated and is likely that a complex antimigraines system with more than 1 site of action is involved. Expand
The locus of action of CGRPergic monoclonal antibodies against migraine: peripheral over central mechanisms.
TLDR
The present review has attempted to summarize and discuss the current evidence on the probable sites of action of these monoclonal antibodies against CGRP or its receptor as a novel pharmacotherapy to treat migraine. Expand
Novel Approaches to the Development of Antimigraine Drugs: A Focus on 5-HT2A Receptor Antagonists
TLDR
The review focuses on the description of 5-HT2A receptors as a promising target for the development of novel antimigraine drugs and new trends in the search for 5- HT2A antagonists among compounds synthesized based on a serotonin bioisostere, benzimidazole. Expand
Human models of migraine — short-term pain for long-term gain
TLDR
The existing experimental models of migraine in humans, including those that exploit nitric oxide, histamine, neuropeptide and prostaglandin signalling, are summarized and the development and use of these models in the discovery of molecular pathways that are responsible for initiation of migraine attacks are described. Expand
The bottom-up approach: Non-invasive peripheral neurostimulation methods to treat migraine: A scoping review from the child neurologist's perspective.
  • C. Börner, Giada Urban, +12 authors M. Bonfert
  • Medicine
  • European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  • 2021
TLDR
Peripheral neurostimulation represents a promising option to complement the multimodal therapy concept for pediatric migraine and opens a new field for research and treatment fitting the requirements of "non-invasiveness" for children. Expand
Efficacy of Calcitonin Gene-Related Peptide Antagonists in the Treatment of Acute Migraine: A Systematic Review and Meta-analysis
TLDR
With regard to pain freedom and pain relief two hours post-dose, CGRP antagonists are more efficacious than placebo in the treatment of acute migraine but there is insufficient evidence to demonstrate superior efficacy of C GRP antagonists over triptans. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 109 REFERENCES
Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis
TLDR
Eletriptan is the most likely of all triptans to produce a favorable outcome and is likely to produce pain-free responses that were sustained in the populations studied, and triptans appear to offer differing treatment effects. Expand
Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial
TLDR
The non-vascular, neural mechanism of action of lasmiditan may offer an alternative means to treat migraine especially in patients who have contra-indications for agents with vasoconstrictor activity. Expand
The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.
TLDR
The role of CGRP in the pathophysiology of migraine and the various treatment modalities that are currently available to target this neuropeptide are discussed. Expand
Towards a Definition of Intractable Headache for Use in Clinical Practice and Trials
TLDR
The definition of intractability is explored to provide some standard against which to test new treatments for patients, who have been called intractable and do not respond to regulatory-approved and other conventional preventive therapies. Expand
Intranasal Civamide for the Acute Treatment of Migraine Headache
TLDR
Based upon the results of this study, intranasal civamide may be effective in the acute treatment of migraine headache and should be substantially more effective for prophylaxis than acutereatment of migraine. Expand
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
TLDR
This study provides Class II evidence that in patients with migraine, telcagepant taken daily reduces headache days by 1.4 days per month compared to placebo and causes 2.5% of patients to have elevations of serum ALT levels. Expand
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
TLDR
Telcagepant 300 mg is effective as an acute treatment for migraine with efficacy comparable to that of zolmitriptan 5 mg, but with fewer associated adverse effects. Expand
Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials
BACKGROUND The triptans, selective serotonin 5-HT(1B/1D) agonists, are very effective acute migraine drugs with a well- developed scientific rationale. Seven different triptans will soon beExpand
Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
TLDR
Oral lasmiditan seems to be safe and effective in the acute treatment of migraine and further assessment in larger placebo-controlled and triptan-controlled trials are needed. Expand
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
TLDR
MK-3207 was effective and generally well tolerated in the acute treatment of migraine and the incidence of adverse events appeared comparable between active treatment groups and placebo, and did not appear to increase with increasing dose. Expand
...
1
2
3
4
5
...